3rd Annual Brain Tumor Symposium:
Current Innovations in Brain Tumor Treatments
November 1, 2013
The Ritz-Carlton, Philadelphia
10 Avenue of The Arts
Philadelphia, PA 19102
Featuring Guest Speakers:
Gene Barnett, MD, MBA
Stuart Grossman, MD
Sidney Kimmel Comprehensive Cancer Center
Eilon Kirson, MD, PhD
Helen A. Shih, MD
Harvard Medical School
This innovative course will be of interest to all specialists working in the field of neuro-oncology: neurosurgeons, neurologists, neuro-radiologists, neuropathologists, nurses and trainees.
This CME Conference offers participants a unique opportunity to hear innovative clinician leaders relate their personal experience with a new technology which shows promise in the treatment of brain tumors. In the Morning Session, this active learning format features an in depth review of seven different innovative approaches to a variety of benign and malignant brain tumors. Participants will gain an understanding of the breadth of clinical research and how experienced healthcare providers approach difficult diseases with novel techniques. In the Afternoon Session, mini-Keynotes from leading practitioners provide evidence for care decisions discussed as key-note lectures and break-out sessions for both physicians and nurses.
The didactic presentations will allow participants to observe and question faculty practitioners as they absorb the latest innovations in brain tumor treatments, and demonstrate how to apply new treatment concepts to tumor biology.
Jefferson Medical College of Thomas Jefferson University is accredited by the ACCME to provide continuing medical education for physicians.
Jefferson Medical College of Thomas Jefferson University designates this live activity for a maximum of 6.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Thomas Jefferson University Hospital is an approved provider of Continuing Nursing Education (CNE) by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. 6.5 is maximum number of contact hours to be awarded to participants.
FACULTY DISCLOSURE STATEMENT
All faculty participating in continuing medical education activities sponsored by Jefferson Medical College are expected to disclose to the activity audience any real or apparent conflict(s) of interest related to the content of their presentation(s). Full disclosure of faculty relationships will be made at this activity.
As an integral part of Jefferson Hospital for Neuroscience, the region's only dedicated hospital for neuroscience, the Department of Neurological Surgery at Jefferson University Hospital is one of the busiest academic neurosurgical programs in the country, offering state-of-the-art treatment to patients with neurological diseases affecting the brain and spine, such as brain tumors, spinal disease, vascular brain diseases, epilepsy, pain, Parkinson's disease and many other neurological disorders (http://www.jefferson.edu/jmc/departments/neurosurgery.html).
The Kimmel Cancer Center (KCC) was founded in 1991 and is one of a select group of cancer centers in the nation designated by the National Cancer Institute. Today, the KCC has approximately 150 members that include physicians and scientists dedicated to discovery and development of novel approaches for cancer treatment. The mission of the Kimmel Cancer Center, a National Cancer Institute-designated cancer center, is to:
- make transformational discoveries of the cellular and molecular biology of the malignant process and the individual's and society's response to it
- effectively translate the latest research discoveries and clinical trials to provide the highest quality of care to all patients including those of diverse ethnic and racial populations
- provide expert and humanitarian care to cancer patients, their families, and those at risk